Finch Therapeutics Group (FNCH) to Release Quarterly Earnings on Friday

Finch Therapeutics Group (NASDAQ:FNCH) is anticipated to release its resultson Friday, March 27th. Analysts expect Finch Therapeutics Group to post earnings of ($30.00) per share and revenue of $3.60 million for the quarter.

Finch Therapeutics Group Price Performance

Shares of Finch Therapeutics Group stock remained flat at $7.30 during trading on Wednesday. 128,123 shares of the company were exchanged, compared to its average volume of 5,025. The company has a market cap of $11.72 million, a price-to-earnings ratio of -0.83 and a beta of 1.18. Finch Therapeutics Group has a 52 week low of $2.00 and a 52 week high of $16.10. The company has a fifty day moving average price of $13.14 and a 200 day moving average price of $13.15.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.